American Vanguard (AVD) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
16 Mar, 2026Executive summary
2025 was a challenging year for the agricultural sector, with net sales declining to $515 million, but operational, digital, and organizational initiatives improved safety, reduced costs, and positioned the company for long-term success.
Adjusted EBITDA for 2025 was $39.2 million, nearly flat compared to $39.1 million in 2024, reflecting cost controls and improved margins.
Rationalization of the Los Angeles facility and headquarters relocation are expected to save $4 million and $0.5 million annually, with both moves to be completed by end of Q2 2026.
Flexible refinancing was secured with two term loans, providing stability and no equity dilution, but at a higher average interest rate.
New product launches and a focus on customer needs are expected to drive higher-margin revenue and long-term growth.
Financial highlights
2025 sales were $515 million, down 6% year-over-year from $547 million, slightly below the $520–$535 million target.
Gross profit margin improved to 29% in 2025 from 22% in 2024, with OpEx as a percentage of sales decreasing to 27%.
Adjusted EBITDA for 2025 was $39.2 million, nearly flat compared to $39.1 million in 2024, but below the $40–$44 million target due to sluggish Q4 sales.
Gross profit rose to $147.6 million in 2025, up 23% year-over-year.
Specialty sales grew 10%, driven by a joint development agreement and growth in mosquito vector solutions.
Outlook and guidance
2026 adjusted EBITDA is projected at $44–$48 million on sales of $530–$550 million.
At least $100 million in additional annual revenue is expected globally over the medium term from new products, with most new product sales ramping up from 2028.
Long-term EBITDA margin target remains at 15%, with a planned CAGR of 4–6% in sales.
Free cash flow is expected to be positive in 2026, given EBITDA projections and CapEx in the $5–$10 million range.
Strategic focus on increasing volumes and new products is expected to drive sales and profitability.
Latest events from American Vanguard
- Q2 sales and margins fell, guidance was cut, and transformation and cost-saving efforts accelerated.AVD
Q2 20242 Feb 2026 - Q3 loss and sales drop driven by recall, but guidance and non-crop growth remain strong.AVD
Q3 202415 Jan 2026 - Transformation plan aims for 15% EBITDA margin and growth in biologicals by 2025.AVD
Gabelli Funds' 16th Annual Specialty Chemicals Symposium26 Dec 2025 - 2024 EBITDA met guidance as debt and inventory fell; 2025 targets higher revenue and margin.AVD
Q4 202424 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve performance-based executive pay.AVD
Proxy Filing2 Dec 2025 - Adjusted EBITDA up 350%, gross margin 29%, and net loss narrowed on strong U.S. crop sales.AVD
Q3 202517 Nov 2025 - Q1 sales dropped 14% with a net loss, but cost cuts and lower debt support recovery.AVD
Q1 202514 Nov 2025 - Adjusted EBITDA nearly doubled and gross margin hit a five-quarter high as net loss narrowed.AVD
Q2 20257 Aug 2025